 July 14, 2021 Breda, the Netherlands argenx Euronext Nasdaq: ARGX, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that it will host a virtual RD Day on Tuesday, July 20, 2021 at 3:00 p.m. CET 9:00 a.m. ET to highlight its argenx 2025 vision and provide an update of its immunology pipeline. The event will introduce the fifth and sixth indications for the Companys FcRn antagonist, efgartigimod, and will include Phase 1 data from its C2 inhibitor, ARGX-117. 